R. Hill Et Al. , "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT," NATURE COMMUNICATIONS , vol.8, 2017
Hill, R. Et Al. 2017. TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. NATURE COMMUNICATIONS , vol.8 .
Hill, R., Madureira, P. A., Ferreira, B., Baptista, I., Machado, S., Colaco, L., ... dos Santos, M.(2017). TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. NATURE COMMUNICATIONS , vol.8.
Hill, Richard Et Al. "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT," NATURE COMMUNICATIONS , vol.8, 2017
Hill, Richard Et Al. "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT." NATURE COMMUNICATIONS , vol.8, 2017
Hill, R. Et Al. (2017) . "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT." NATURE COMMUNICATIONS , vol.8.
@article{article, author={Richard Hill Et Al. }, title={TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT}, journal={NATURE COMMUNICATIONS}, year=2017}